5-(carbamoylamino)-N-methylpentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-(carbamoylamino)-N-methylpentanamide
• 化学式: C₇H₁₅N₃O₂
• 分子量: 173.21
• InChiKey: FMIJSYPAUXPCHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
  申请人：Genentech, Inc.

  公开号：EP3082875B1

  公开（公告）日：2020-11-25
• [EN] FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION<br/>[FR] POLYPEPTIDES CONTENANT FC AYANT UNE GLYCOSYLATION MODIFIÉE ET UNE FONCTION EFFECTRICE RÉDUITE
  申请人：GENZYME CORP

  公开号：WO2014043361A1

  公开（公告）日：2014-03-20

  Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• [EN] HYPERGLYCOSYLATED BINDING POLYPEPTIDES<br/>[FR] POLYPEPTIDES DE LIAISON HYPERGLYCOSYLÉS
  申请人：GENZYME CORP

  公开号：WO2014164503A1

  公开（公告）日：2014-10-09

  Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING<br/>[FR] CONJUGAISON ANTICORPS-MÉDICAMENT SPÉCIFIQUE D'UN SITE PAR GLYCO-INGÉNIERIE
  申请人：GENZYME CORP

  公开号：WO2014164534A2

  公开（公告）日：2014-10-09

  The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.